RADNOSTIX INC

Radnostix Inc. entered into an Asset Purchase Agreement to acquire the Lara System technology platform and Ellexa Explorer Software from Lucerno Dynamics, LLC for an initial $900,000, paid partly in cash and partly in common stock, with potential additional stock and cash earn-out payments based on milestones. Concurrently, the company secured a $500,000 convertible promissory note from a related party and amended several historic related-party notes totaling $1.62 million, extending their maturity by three years and introducing new conversion terms.

Radnostix Inc. has filed its Definitive Proxy Statement for the 2026 Annual Meeting of Shareholders, scheduled for July 16, 2026. The meeting agenda includes the election of five directors, ratification of Haynie & Company as the independent auditor for fiscal year 2026, and approval of the Radnostix 2026 Incentive Plan. The company is providing access to proxy materials via the internet and encouraging shareholders to vote by mail, telephone, or online. The record date for voting eligibility is May 26, 2026.

Radnostix, Inc. announced a modification to its Series C Convertible Redeemable Preferred Stock. The company received approval from a majority of Series C Preferred Stock holders to extend the maturity date by an additional year to February 28, 2028. All other terms of the Series C Preferred Stock remain unchanged. A Certificate of Amendment was filed with the Secretary of State of Texas to reflect this modification.

RADNOSTIX INC. reported a significant increase in net loss to $(1.35) million for the three months ended March 31, 2026, compared to $(0.11) million in the prior year, with product sales decreasing by 26.55%. The company mutually terminated its $12.5 million asset purchase agreement for its Fluorine Products segment, citing the buyer's inability to secure funding and the company's belief in the assets' appreciated value. RADNOSTIX also noted ongoing liquidity challenges and dependence on key suppliers, alongside efforts to expand its Medical Device segment and strategic partnerships.